Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 13/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 3/20 | 0.32 |
| ▸ | RPTOR | Q8N122 | 6/20 | 0.31 |
| ▸ | MLST8 | Q9BVC4 | 6/20 | 0.31 |
| ▸ | RICTOR | Q6R327 | 4/20 | 0.31 |
| ▸ | MAPKAP1 | Q9BPZ7 | 4/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16205594 | 0.88 | CCNT1 (0.33) | MAP3K14 | |
| SCHEMBL16205386 | 0.87 | CHUK (0.37) | EGFRMAP3K14 | |
| SCHEMBL16205749 | 0.87 | MTOR (0.32) | MTORMAP3K14RPTORMLST8RICTOR | |
| SCHEMBL16205609 | 0.80 | PIK3CA (0.39) | MTORPIK3CAEGFRMAP3K14PIK3R1 | |
| SCHEMBL16205376 | 0.79 | PIK3CA (0.34) | MTORPIK3CAEGFRMAP3K14RPTOR | |
| SCHEMBL16205402 | 0.78 | MAP3K14 (0.55) | EGFRMAP3K14 | |
| SCHEMBL16205371 | 0.78 | CHUK (0.35) | MTORPIK3CAPIK3R1 | |
| SCHEMBL21096798 | 0.78 | ADORA2A (0.38) | MTORPIK3CAMAP3K14 | |
| SCHEMBL16205593 | 0.77 | DYRK1A (0.45) | EGFRMAP3K14TYK2 | |
| SCHEMBL16205737 | 0.74 | MAP3K14 (0.31) | MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-9643964-B2 | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-C]pyridine derivatives as NIK inhibitors for the treatment of cancer | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-09 | — | — | US | disclosed |
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA N.V. (BE) | 2016-03-17 | — | — | US | disclosed |
| WO-2014174021-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075699-A1 | 3-(2-AMINOPYRIMIDIN-4-YL)-5-(3-HYDROXYPROPYNYL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS FOR THE TREATMENT OF CANCER | NFKBIA, IKBKG, MAP3K14 | MTOR 475/4885PIK3CA 274/4885EGFR 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.